Basic Information
Xaluprine (previously Mercaptopurine Nova Laboratories)
Regulatory Information
EMEA/H/C/002022
Authorised
March 9, 2012
July 21, 2011
17
February 13, 2025
Company Information
Ireland
3rd Floor, Ulysses House Foley Street Dublin 1, D01 W2T2
NOVA LABORATORIES IRELAND LIMITED
Active Substances Detail
6-mercaptopurine monohydrate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.